DTIL (Precision BioSciences) Beginning Cash Position: $137.15 Mil (As of Mar. 2026)


DTIL Precision BioSciences Inc DTIL
50 GF Score
Price $8.77
GF Value $1.83
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Precision BioSciences Beginning Cash Position?

Precision BioSciences DTIL -4.37% 50 Beginning Cash Position is $137.15 Mil as of Mar. 2026. GuruFocus rates DTIL with a GF Score™ of 50/100 and a GF Value™ of $1.83 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Precision BioSciences's Beginning Cash Position for the quarter that ended in Mar. 2026 was $137.15 Mil.

Precision BioSciences's quarterly Beginning Cash Position declined from Sep. 2025 ($84.81 Mil) to Dec. 2025 ($71.21 Mil) but then increased from Dec. 2025 ($71.21 Mil) to Mar. 2026 ($137.15 Mil).

Precision BioSciences's annual Beginning Cash Position declined from Dec. 2023 ($189.58 Mil) to Dec. 2024 ($116.68 Mil) and declined from Dec. 2024 ($116.68 Mil) to Dec. 2025 ($108.47 Mil).

Precision BioSciences Beginning Cash Position Related Terms

Precision BioSciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Precision BioSciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precision BioSciences Beginning Cash Position Chart

Precision BioSciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 89.80 143.66 189.58 116.68 108.47

Precision BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.47 99.79 84.81 71.21 137.15
DTIL
50GF Score
Precision BioSciences Inc DTIL
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Precision BioSciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $137.15 Mil mean?
Precision BioSciences (DTIL) has a Beginning Cash Position of $137.15 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Precision BioSciences and its competitors.
Is Precision BioSciences' Beginning Cash Position too high?
Precision BioSciences' current Beginning Cash Position is $137.15 Mil. Overall, Precision BioSciences has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' Beginning Cash Position compare to NBP and HUMA?
Precision BioSciences' Beginning Cash Position of $137.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Precision BioSciences and its competitors. Precision BioSciences's current Beginning Cash Position is $137.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $8.77 — trading 379% above its estimated fair value. The current Beginning Cash Position is $137.15 Mil. Precision BioSciences' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current Beginning Cash Position is $137.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precision BioSciences (DTIL) Overvalued in 2026?

Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued. The current stock price of $8.77 is trading 379% above its estimated GF Value™ of $1.83. GuruFocus considers Precision BioSciences to be Significantly Overvalued.

Key valuation signals for DTIL:

  • Beginning Cash Position: $137.15 Mil
  • GF Value™: $1.83 vs. price of $8.77 (379% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precision BioSciences Business Description

Other Exchanges PBS0:Germany
Address 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
50GF Score

Get the complete analysis for DTIL

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.77
Price
$1.83
GF Value